卡培他滨联合奥沙利铂挽救治疗蒽环类或泰素耐药的晚期乳腺癌临床观察  

Clinical Evaluation of Capecitabine Combined with Oxaliplatin as Salvage Treatment for Patients with Advanced/Metastatic Breast Cancer Resistant to Anthracycline or Taxane

作　　者：龙建林[1] 任章霞[1] 易全会 杨宁[1] 

机构地区：[1]广安市人民医院,四川广安638000

出　　处：《川北医学院学报》2010年第4期313-316,共4页Journal of North Sichuan Medical College

摘　　要：目的:评价卡培他滨联合奥沙利铂治疗蒽环类或泰素耐药的晚期乳腺癌的近期疗效、远期生存及安全性。方法:32例经细胞学或组织学证实的对蒽环类或泰素耐药的晚期乳腺癌患者接受卡培他滨联合奥沙利铂治疗。研究终点为:客观有效率(ob jective response rate,ORR)、中位无进展生存期(m ed ian progression-free survival,PFS)、中位生存期(m ed ian overallsurvival,OS)及安全性。结果:中位随访12.7月,32例患者均可接受疗效及生存评价,其中完全缓解1例(comp lete response,CR),部分缓解10例(partial response,PR),稳定12例(stab le d isease,SD),进展9例(progression d isease,PD)。RR为34.4%,中位PFS为6.2月,中位OS为13.7月。3/4度中性粒细胞减少、腹泻及手足综合症发生率分别为:15.7%、12.5%和6.3%。结论:卡培他滨联合奥沙利铂治疗蒽环类或泰素耐药的晚期乳腺癌能够取得较好的疗效及生存期,副作用轻。Objective： To evaluate the response rate,long-term survival and safety of capecitabine combined with oxaliplatin as salvage treatment for patients with metastatic breast cancer resistant to anthracycline or taxane.Methods： 32 cytologically or histologically confirmed patients resistant to anthracycline or taxane enrolled and achieved the treatment of capecitabine combined with oxaliplatin.The study endpoints were objective RR,median PFS,median OS and safety.Results： The median following time was 16.1 months and all of the 32 patients could be evaluated of response and survival.One achieved CR,10 achieved PR,12 achieved SD and 9 had PD.The RR was 34.4%,PFS was 6.2 months and OS was 13.7 months.3rd to 4th grade neutropenia,diarrhea and hand-and-foot syndrome were 15.7%,2.5% and 6.3%,respectively.Conclusion： The combination of capecitabine with oxaliplatin as salvage treatment for patients with advanced/metastatic breast cancer resistant to anthracycline or taxane could achieve superior response and survival and the side-effects were tolerable.

关 键 词：卡培他滨 奥沙利铂 晚期乳腺癌 

分 类 号：R711.75[医药卫生—妇产科学]